Evidence map›Paper›PMID 41758159›Full record

ArticlePacific Symposium on Biocomputing. Pacific Symposium on Biocomputing2026

Steering Protein Generative Models at Test-Time for Guided AAV2 Capsid Design.

Ben Viggiano, Wenhui Sophia Lu, Xiaowei Zhang, Luis S Mille-Fragoso, Xiaojing J Gao, Euan Ashley, Wing Hung Wong

Abstract read
In one paragraph

Article in Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ben ViggianoDepartment of Biomedical Data Science, Stanford University, Stanford, CA, USA.
Wenhui Sophia LuDepartment of Statistics, Stanford University, Stanford, CA, USA.
Xiaowei ZhangDepartment of Bioengineering, Stanford University, Stanford, CA, USA4Sarafan ChEM-H, Stanford University, Stanford, CA, USA.
Luis S Mille-FragosoDepartment of Bioengineering, Stanford University, Stanford, CA, USA4Sarafan ChEM-H, Stanford University, Stanford, CA, USA5Stanford Bio-X, Stanford University, Stanford, CA, USA.
Xiaojing J GaoStanford Bio-X, Stanford University, Stanford, CA, USA8Department of Chemical Engineering, Stanford University, Stanford, CA, USA.
Euan AshleyDepartment of Biomedical Data Science, Stanford University, Stanford, CA, USA6Department of Medicine, Stanford University, Stanford, CA, USA7Center for Undiagnosed Diseases, Stanford University, Stanford, CA, USA.
Wing Hung WongDepartment of Biomedical Data Science, Stanford University, Stanford, CA, USA2Department of Statistics, Stanford University, Stanford, CA, USA5Stanford Bio-X, Stanford University, Stanford, CA, USA.

Funding

New Statistical Methods for Medical Signals and ImagesR01GM134483 · NIGMS · STANFORD UNIVERSITY · PI Iain M Johnstone · 2019 to 2026
$3.9M
NIGMS NIH HHS R01 GM134483
6 · The paper itself

Abstract

Recent advances in protein generative models have created new opportunities for protein engineering. However, a significant challenge remains in effectively steering these models to generate sequences with specific, desired functionalities, especially when these properties are defined by "black-box" or non-differentiable fitness functions. To address this, we present ProVADA+, a model-agnostic framework that guides pretrained generative models at testtime without costly retraining. Our approach introduces a reinforcement learning-based adaptive masking technique (MADA-DUCB) that significantly accelerates convergence. We demonstrate this framework on the challenging task of designing novel Adeno-Associated Virus 2 (AAV2) capsids. By coupling a ProteinMPNN generative prior with a fine-tuned AAV viability oracle, our method successfully navigates the rugged fitness landscape where unguided random mutagenesis is ineffective-with prior experiments showing as few as 0.3% of variants with six or more mutations are viable. In its final iterations, ProVADA generated a pool of novel candidates with a mean viral selection score of 2.72, consistently scoring highly viable variants while maintaining a diverse range of sequence similarity to the wildtype sequence. Our results show that ProVADA provides a powerful and efficient framework for accelerating the design of proteins with complex, user-defined properties.

Indexed as

Capsid ProteinsDependovirusProtein EngineeringAlgorithmsCapsidComputational BiologyGenerative Artificial IntelligenceHumansMutationReinforcement Machine LearningCapsid Proteins

Identifiers

PMID41758159
PMCPMC12952671

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.